We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+43%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$926M
AUM Growth
+$212M
Cap. Flow
-$7.45M
Cap. Flow %
-0.8%
Top 10 Hldgs %
29.66%
Holding
99
New
14
Increased
24
Reduced
46
Closed
5

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$17.6M
2
BAX icon
Baxter International
BAX
+$8.28M
3
XLRN
Acceleron Pharma
XLRN
+$8.19M
4
UNH icon
UnitedHealth
UNH
+$7.16M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.1M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$10.7M
2
ESPR
Esperion Therapeutics
ESPR
+$7.02M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$6.08M
4
NKTR icon
Nektar Therapeutics
NKTR
+$5.93M
5
MGNX icon
MacroGenics
MGNX
+$5.65M

Sector Composition

Rank Sector Weight
1 Healthcare 94.86%
2 Communication Services 1.03%
3 Energy 0.07%
4 Technology 0.06%
5 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$41.7M 4.5%
750,000
-250,000
-25% -$10.7M
VRTX icon
2
Vertex Pharmaceuticals
VRTX
$121B
$39.9M 4.31%
137,500
+22,500
+20% +$6.1M
UNH icon
3
UnitedHealth
UNH
$376B
$31M 3.35%
105,000
+25,000
+31% +$7.16M
ABBV icon
4
AbbVie
ABBV
$443B
$29.5M 3.18%
300,000
-30,000
-9% -$2.64M
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$11.6B
$23.4M 2.53%
190,000
+5,155
+3% +$512K
BMY icon
6
Bristol-Myers Squibb
BMY
$133B
$22.3M 2.41%
380,000
+30,000
+9% +$1.79M
NVCR icon
7
NovoCure
NVCR
$1.73B
$22.2M 2.4%
375,000
+15,000
+4% +$987K
ESPR
8
DELISTED
Esperion Therapeutics
ESPR
$21.8M 2.36%
425,000
-167,798
-28% -$7.02M
HUM icon
9
Humana
HUM
$43.7B
$21.3M 2.3%
55,000
+10,000
+22% +$3.74M
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
$21.3M 2.3%
190,000
+30,000
+19% +$3.19M
CI icon
11
Cigna
CI
$73.7B
$20.6M 2.23%
110,000
+5,000
+5% +$949K
MGNX icon
12
MacroGenics
MGNX
$235M
$18.8M 2.04%
675,000
-325,000
-33% -$5.65M
NKTR icon
13
Nektar Therapeutics
NKTR
$2.39B
$18.3M 1.98%
52,667
-19,000
-27% -$5.93M
GILD icon
14
Gilead Sciences
GILD
$162B
$17.7M 1.91%
+230,000
New +$17.6M
LLY icon
15
Eli Lilly
LLY
$1.02T
$17.2M 1.86%
105,000
+5,000
+5% +$767K
ELV icon
16
Elevance Health
ELV
$81.5B
$17.1M 1.85%
65,000
– –
ABT icon
17
Abbott
ABT
$183B
$16.9M 1.83%
185,000
+15,000
+9% +$1.36M
AXNX
18
DELISTED
Axonics, Inc. Common Stock
AXNX
$16.5M 1.78%
470,000
+5,000
+1% +$172K
ABMD
19
DELISTED
Abiomed Inc
ABMD
$16.4M 1.77%
68,000
-20,000
-23% -$4.02M
IMMU
20
DELISTED
Immunomedics Inc
IMMU
$16.3M 1.76%
460,000
-130,000
-22% -$3.8M
MYOK
21
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$15.5M 1.67%
160,000
-20,000
-11% -$1.67M
BHVN
22
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$15.4M 1.66%
210,000
+70,000
+50% +$3.73M
JAZZ icon
23
Jazz Pharmaceuticals
JAZZ
$15.9B
$15.1M 1.63%
137,032
+17,032
+14% +$1.88M
GH icon
24
Guardant Health
GH
$21.7B
$15M 1.62%
185,000
+10,000
+6% +$806K
CNC icon
25
Centene
CNC
$30.7B
$14.9M 1.61%
234,378
+59,378
+34% +$3.87M
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2020 Portfolio in Review

As of Q2 2020, Rhenman & Partners Asset Management held 99 positions worth $926M, up 30% from $714M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rhenman & Partners Asset Management's Q2 2020 filing shows 14 new, 24 increased, 46 reduced and 5 closed positions. Its largest new stake was Gilead Sciences: 230,000 shares worth $17.7M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $10.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Communication Services and Energy.

  • Rhenman & Partners Asset Management's largest Q2 2020 buy was Gilead Sciences: 230,000 shares worth $17.7M.
  • Rhenman & Partners Asset Management added most to Acceleron Pharma in Q2 2020, an estimated $8.19M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2020 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $10.7M.
  • Rhenman & Partners Asset Management fully exited Stemline Therapeutics, Inc. in Q2 2020, selling an estimated $3.15M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 30% of its $926M portfolio in Q2 2020.
  • Rhenman & Partners Asset Management opened 14 new positions and closed 5 in Q2 2020.
  • Rhenman & Partners Asset Management's portfolio value rose 30% quarter-over-quarter to $926M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2020, filed 16 Jul 2020.